Saladax Biomedical Launches Game-Changing Assays at AACC 2018

Saladax Biomedical Inc. (Bethlehem, PA, USA), a diagnostics company providing kits to test drug blood levels for adherence and personalized dose management, announced the launch of its new line of tests for psychiatry in Europe (CE mark) at AACC 2018. Saladax develops novel blood tests that increase the impact of personalized medicine by bringing chemotherapeutic drug monitoring to oncologists and adherence testing to psychiatrists.

Saladax’s MyCare Psychiatry line provides greater clarity on the causes of treatment failure and may help distinguish medication non-response from lack of adherence. The MyCare Psychiatry panel of tests addresses a critical, unmet need for quickly identifying levels of antipsychotic drugs in a patient’s body. A one-hour turnaround time is possible in a STAT mode within a laboratory. Rapid testing has the potential to reduce treatment failures and to positively impact patient management. The MyCare Psychiatry line will launch with tests for clozapine, quetiapine, aripiprazole, risperidone, olanzapine and paliperidone, five of which are currently available for sale in Europe.


“We engineered the MyCare Psychiatry line based on psychiatrists’ needs and extensive research of the market,” said Dr. Salvatore J. Salamone, Founder/CEO. “The result is a game-changer that delivers clinicians access to rapid quantitative blood levels of the psychotherapeutic drugs their patients are on. The MyCare line delivers a fast and accurate result, giving physicians timely information of high medical value, needed to better treat their patients.”

Related Links:
Saladax Biomedical